Dogwood Therapeutics Files 2024 10-K
Ticker: DWTX · Form: 10-K · Filed: Mar 31, 2025 · CIK: 1818844
| Field | Detail |
|---|---|
| Company | Dogwood Therapeutics, INC. (DWTX) |
| Form Type | 10-K |
| Filed Date | Mar 31, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-K, pharmaceuticals, financials
TL;DR
Dogwood Therapeutics 2024 10-K is in. Financials for year-end Dec 31, 2024 are out.
AI Summary
Dogwood Therapeutics, Inc. filed its 2024 10-K on March 31, 2025, reporting its financial performance for the fiscal year ending December 31, 2024. The company, formerly Virios Therapeutics, Inc., is involved in the pharmaceutical preparations industry. Key financial data and events from the filing are detailed, including information on stock, retained earnings, and paid-in capital as of December 31, 2024.
Why It Matters
This filing provides investors and stakeholders with a comprehensive overview of Dogwood Therapeutics' financial health and operational status for the fiscal year 2024, crucial for investment decisions.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Dogwood Therapeutics is subject to significant regulatory, clinical trial, and market risks inherent in drug development and commercialization.
Key Numbers
- 2213.8044 — Financial Data Point (Appears multiple times, likely representing a significant financial metric for 2024.)
- 0.04 — Financial Data Point (A small decimal value, potentially related to stock or other financial ratios.)
- 0.0001 — Financial Data Point (A very small decimal value, possibly related to per-share data or minor financial adjustments.)
Key Players & Entities
- Dogwood Therapeutics, Inc. (company) — Filer of the 10-K
- Virios Therapeutics, Inc. (company) — Former name of Dogwood Therapeutics
- 20241231 (date) — Fiscal year end for the 10-K report
- 20250331 (date) — Filing date of the 10-K
- 44 Milton Avenue, Alpharetta, GA 30009 (address) — Business and mailing address
FAQ
What were the primary business activities of Dogwood Therapeutics, Inc. during the fiscal year 2024?
The filing indicates Dogwood Therapeutics, Inc. is in the Pharmaceutical Preparations industry (SIC code 2834), suggesting activities related to the development and manufacturing of pharmaceutical products.
When did Dogwood Therapeutics, Inc. change its name from Virios Therapeutics, Inc.?
The company formerly known as Virios Therapeutics, Inc. changed its name on December 17, 2020.
What significant events occurred after the fiscal year end of 2024, as noted in the filing?
The filing notes a 'Registered Direct Offering' on March 12, 2025, as a subsequent event.
What are the key balance sheet components reported as of December 31, 2024?
The filing references key components such as Treasury Stock (Common), Retained Earnings, Additional Paid-In Capital, and Accumulated Other Comprehensive Income as of December 31, 2024.
What is the company's primary industry classification?
Dogwood Therapeutics, Inc. is classified under Pharmaceutical Preparations with SIC code 2834.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 31, 2025 regarding Dogwood Therapeutics, Inc. (DWTX).